Graham Number Gaps: Indegene & Sammaan Capital

Graham Number Gaps: Indegene and Sammaan Capital Stand Out Benjamin Graham never met a pharma tech company. He died in 1976, long before anyone imagined a firm like [Indegene](/stock/INDGN) — a Bengaluru-based company that helps global life sciences giants commercialize drugs faster using data and digital tools. Yet his formula, the Graham Number, flags INDGN as one of the most arithmetically undervalued stocks on the Indian screen right now. At ₹555.80, it trades 61.2% below a Graham Number of ₹1,278.09. That's not a small gap. That's a canyon. Yesterday's coverage on this platform examined LIC Housing Finance and J&K Bank, two names where the Graham discount made intuitive sense — financials trading below book in a rate-sensitive cycle. Indegene and [Sammaan Capital](/stock/SAMMAANCAP) are a different story. One carries a P/E of 33.44x, pricing in meaningful growth. The other sits at 9.70x, pricing in something closer to doubt. Both are worth understanding before assuming the Graham Number alone settles the argument. What the Arithmetic Actually Says The Graham Number is calculated as the square root of (22.5 × EPS × Book Value Per Share). It's a blunt instrument by design — Graham wanted a single conservative threshold, not a discounted cash flow model with seventeen assumptions. When a stock trades 61% below that threshold, one of two things is true: the market is deeply wrong, or the inputs — earnings and book value — are telling a story the price already knows. For NSE: INDGN, the tension is obvious. A P/E of 33.44x is not a value multiple. It reflects the market's expectation that Indegene will compound earnings meaningfully over the next several years. The company listed in May 2023 at ₹452 per share and has built a reputation as a pure-play life sciences commercialization partner, serving clients across the US, Europe, and Asia. Its revenue mix is heavily weighted toward regulated markets, which adds currency exposure but also pricing power. The wide G...